Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Barrett, Susan ^a   Mohr, Peter G ^a   Schmidt, Peter M ^a   McKimm Breschkin, Jennifer L ^a  

^a CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLNEURAMINIC ACID; OSELTAMIVIR; PERAMIVIR; SIALIDASE; ZANAMIVIR; 2-DEOXY-2,3-DEHYDRO-N-ACETYLNEURAMINIC ACID; CYCLOPENTANE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; N ACETYL 2,3 DIDEHYDRO 2 DEOXYNEURAMINIC ACID; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DISSOCIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; IC 50; INCUBATION TIME; INFLUENZA VIRUS; NONHUMAN; PHENOTYPE; REACTION TIME; BINDING COMPETITION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HUMAN; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; KINETICS; METABOLISM; METHODOLOGY; MUTATION; ORTHOMYXOVIRUS; PROTEIN BINDING; TIME;

ORTHOMYXOVIRIDAE;

BINDING, COMPETITIVE; CYCLOPENTANES; ENZYME ASSAYS; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INHIBITORY CONCENTRATION 50; KINETICS; MUTATION; N-ACETYLNEURAMINIC ACID; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; PROTEIN BINDING; SUBSTRATE SPECIFICITY; TIME FACTORS; VIRAL PROTEINS; ZANAMIVIR;

EID: 80051772538     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023627     Document Type: Article

References (28)

1. Birnkrant D, Cox E, (2009) The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. New Engl J Med 361: 2204-2207.
2. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM, (1992) The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14: 327-332.
3. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418-423.
4. Pegg MS, von Itzstein M, (1994) Slow-binding inhibition of sialidase from influenza virus. Biochem Mol Biol Int 32: 851-858.
5. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, et al. (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6: 735-746.
6. Baum EZ, Wagaman PC, Ly L, Turchi I, Le J, et al. (2003) A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res 59: 13-22.
7. Kati WM, Saldivar AS, Mohamadi F, Sham HL, Laver WG, et al. (1998) GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains. Biochem Biophys Res Commun 244: 408-413.
8. Wang MZ, Tai CY, Mendel DB, (2002) Mechanism by which mutations at His274 alter sensitivity of influenza a virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 46: 3809-3816.
9. Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, et al. (1995) Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 214: 475-484.
10. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, et al. (1998) Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 72: 2456-2462.
11. Oakley AJ, Barrett S, Peat TS, Newman J, Streltsov VA, et al. (2010) Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem 53: 6421-6431.
12. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB, (1979) Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl- alpha-D-N-acetylneuraminate) substrate. Analytical Biochemistry 94: 287-296.
13. Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, et al. (2000) Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 280: 291-300.
14. Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, et al. (2003) Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the Neuraminidase Inhibitor Susceptibility Network. J Clin Microbiol 41: 742-750.
15. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, et al. (2006) Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50: 2395-2402.
16. Tashiro M, McKimm-Breschkin JL, Saito T, Klimov A, Macken C, et al. (2009) Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir Ther 14: 751-761.
17. Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW, et al. (2006) Neuraminidase inhibitor-resistant and-sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 50: 1872-1874.
18. Smith BJ, McKimm-Breschkin JL, McDonald M, Fernley RT, Varghese JN, et al. (2002) Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 45: 2207-2212.
19. McKimm-Breschkin JL, Selleck P, Usman TB, Johnson MA, (2007) Reduced Sensitivity of influenza A (H5N1) to Oseltamivir. Emerg Infect Dis Vol. 13: 1354-1357 • wwwcdcgov/eid •.
20. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
21. Chong AK, Pegg MS, Taylor NR, von Itzstein M, (1992) Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. Eur J Biochem 207: 335-343.
22. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, et al. (2010) Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 6: e1000786.
23. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P, (2006) Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 69: 39-45.
24. Bantia S, Upshaw R, Babu YS, (2011) Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme. Antiviral Research.
25. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, et al. (2003) Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 47: 2264-2272.
26. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, et al. (2007) Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 44: 197-202.
27. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al. (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258-1261.
28. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, et al. (2010) The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 17: 1266-1268.